Invion (ASX:IVX) has announced that RMW Cho Group (RMWC), the licensor of the Photosoft technology, has completed a Phase 2 prostate cancer trial using a sublingual formulation of INV043.
Invion said that RMWC provided a clinical study summary report collated by Scendea. It included information received and relied upon from RMWC based on the results of the investigator-led, open-label trial that was fully funded by RMWC.
The Phase 2 prostate cancer trial used six treatment cycles of INV043 as a monotherapy. It was found to be safe and well tolerated by patients with no serious adverse events experienced, and all reported side effects were mild.
Regarding efficacy signals, 40 per cent of patients showed a positive response to the treatment, with 10 per cent demonstrating complete regression. In addition, 44 per cent of patients had negative Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) results three months post-treatment.
Invion said the report concluded that "the favourable safety profile and the preliminary efficacy results are promising and warrant further investigation of INV043".
Invion's executive chair and CEO, Thian Chew, said, "It's very exciting to see these results for our lead cancer candidate, INV043. The results showed that INV043 can be safely administered and activated with light to treat prostate cancer. It also highlighted its potential to be safely administered systemically to patients, including via sublingual and even IV routes.
"Together with the positive efficacy signals from this trial, this points to the prospect of INV043 to become an effective treatment for prostate cancer without the devastating side effects that can be associated with conventional treatments."
